REVIVA PHARMACEUTICALS HOLDINGS, INC. Annual Report Summary

I’m putting together this guide to help you understand how Reviva Pharmaceuticals performed this year. My goal is to break down their complex filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Reviva is a clinical-stage pharmaceutical company. Think of them as a science lab rather than a store; they aren't selling medicine yet. Their main project is Brilaroxazine, a potential treatment for schizophrenia. Their year focused on one goal: funding the tests needed to reach the finish line of FDA approval.

2. Financial performance

Reviva is currently in a "spending" phase. For the year ending December 31, 2025, the company reported $0 in sales. Their financial report is essentially a list of bills. They reported an operating loss of $35.4 million, driven by $26.8 million in research costs and $8.6 million in administrative expenses. Because they have no revenue, they rely entirely on raising outside capital to fund their operations.

3. Major wins and challenges

The defining theme of 2025 was the constant need for cash. To keep research moving, the company sold more stock through public offerings, raising $15 million.

While this kept the company operational, it came at a cost to existing shareholders. The company issued many warrants—coupons that allow holders to buy stock at a set price. Every time they issue new shares or warrants, they create more pieces of the company pie. By the end of 2025, the number of shares outstanding grew significantly, which reduces the ownership percentage and potential value of your existing holdings.

4. Financial health

Reviva is operating on a very tight leash. As of December 31, 2025, they held about $4.2 million in cash. To maintain their listing on the Nasdaq, they executed a 1-for-20 reverse stock split in early 2026. They are currently living paycheck to paycheck, with enough cash to last only a few months without raising additional capital.

5. Key risks

The primary risk is dilution. Because the company must issue new shares to raise cash, your percentage of ownership shrinks over time. Furthermore, because they have no sales, their entire value rests on the success of their drug trials. If the Brilaroxazine trial fails, the company has no backup plan, which could lead to a total loss of value.

6. Competitive positioning

Reviva is a small player in a massive industry. They compete against established pharmaceutical giants that have billions in the bank. Reviva’s survival depends entirely on Brilaroxazine proving to be safer or more effective than the drugs already on the market.

7. Future outlook

The company enters 2026 focused on one goal: surviving until the results of their RECOVER-2 trial are released. For investors, this is a high-stakes waiting game. Watch to see if they can reach this milestone without issuing more shares, which would further lower the value of your investment.

8. Market trends

The FDA acts as the ultimate referee for the company's future. Any change in how the government evaluates drugs could impact the company overnight. Additionally, high interest rates make borrowing money expensive for a company with no sales, forcing Reviva to rely on selling more stock, which continues to impact current shareholders.

---

Investor Takeaway: Reviva is a high-risk, speculative investment. Because they have no revenue and very little cash, they are entirely dependent on successful clinical trial results and their ability to raise more money from investors. Before investing, ask yourself if you are comfortable with the high probability of further share dilution and the "all-or-nothing" nature of their drug development pipeline.